Westminster, CA – May 21, 2020 – BioLargo, Inc.
(OTCQB:BLGO), developer of sustainable technologies and a full-service
environmental engineering company, today announced that its patented CupriDyne®
technology has been proven in a third-party study to be effective in
inactivating SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic.
The study was conducted by researchers at the Galveston National Laboratory
(GNL), a biosafety level (BSL) level 3 lab associated with the University of
Texas Medical Branch (UTMB).
To introduce a product to market that can make a COVID-19
claim, BioLargo will need approval from the Environmental Protection Agency. It
has retained an EPA consultant and is considering the options to fast-track an
application, including through a special Section 18 exemption. Management
believes that a CupriDyne based COVID-19 product would provide a safe, environmentally
friendly spray or misting product to enable effective decontamination of
enclosed spaces and public places, and would provide an additional tool for
protection to front-line workers and vulnerable persons as governments begin to
allow businesses to reopen.
Results of the study conducted by the Galveston National Lab
have been published here: https://www.biorxiv.org/content/10.1101/2020.05.08.082701v1
The study concluded:
“The novel iodine complex tested herein offers a safe and
gentle alternative
to conventional
disinfectants for use on indoor and outdoor surfaces.”
Dennis P. Calvert, President &
CEO of BioLargo commented, “Iodine has a long history of use as a first-line
disinfectant and antiviral agent, so it does not come as a surprise that
CupriDyne was found to be effective against SARS-CoV-2. Research also shows
that iodine-containing solutions were used in previous pandemics, including the
1918 Spanish Flu, and the SARS and MERS outbreaks in 2006 and 2013. Our
products offer a unique, non-toxic and non-staining form of iodine that is exceptionally
suited to help stop spread of this virus.”
About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products
and environmental engineering solutions provider driven by a mission to “make
life better”. We feature unique
disruptive solutions to deliver clean air, clean water and a clean, safe
environment (www.biolargo.com). Our
engineering division features experienced professional engineers dedicated to
integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our
industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne
Clean Industrial Odor Eliminator (www.cupridyne.com),
which eliminates the odor-causing compounds and VOCs rather than masking them,
and is now winning over leading companies in the solid waste handling and
wastewater industries and other industries that contend with malodors and VOCs.
Our subsidiary BioLargo Water (www.biolargowater.ca)
develops the Advanced Oxidation System "AOS," a disruptive industrial
water treatment technology designed to eliminate waterborne pathogens and
recalcitrant contaminants with better energy-efficiency and lower operational
costs than incumbent technologies. We are a minority stockholder of and
licensor to our subsidiary Clyra Medical (www.clyramedical.com),
which features effective and gentle solutions for chronic infected wounds to
promote infection control and regenerative tissue therapy.
About Galveston National Laboratory/UTMB
The Galveston National Laboratory (GNL) is a sophisticated
high containment research facility that serves as a critically important
resource in the global fight against infectious diseases. The GNL is located on
the campus of the University of Texas Medical Branch and operates under the
umbrella of UTMB’s Institute for Human Infections and Immunity.
The National Institute of Allergy and Infectious Diseases
(NIAID) provides funding for the BSL4 laboratories and operations at the GNL,
and the lab’s top priority is research to develop diagnostics, therapeutics and
vaccines to combat the most dangerous diseases in the world.
Researchers at the GNL are internationally known for their
expertise working with pathogens including Ebola and Marburg, emerging
infectious diseases like MERS, and mosquito borne viruses like Zika and
Chikungunya. The Galveston National Laboratory is home to research that is
funded by NIAID, the U.S. Department of Defense, the U.S. Centers for Disease
Control & Prevention and other federal agencies, as well as academic
partners, private foundations, and the Biopharmaceutical industry.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release includes “forward-looking
statements” within the meaning of the safe harbor provisions of the United
States Private Securities Litigation Reform Act of 1995. Actual results may
differ from expectations, estimates and projections and, consequently, you
should not rely on these forward-looking statements as predictions of future
events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,”
“predicts,” “potential,” “continue,” and similar expressions are intended to
identify such forward-looking statements. These forward-looking statements
involve significant risks and uncertainties that could cause the actual results
to differ materially from the expected results.
No comments:
Post a Comment